Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 32Sarcoma 29Neoplasm Metastasis 17Ovarian Neoplasms 10Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Kidney Neoplasms 6Recurrence 5Lung Neoplasms 5Liposarcoma 5Thyroid Neoplasms 4Melanoma 4Leiomyosarcoma 4Hemangiosarcoma 4Urinary Bladder Neoplasms 3Solid Tumors 3Pancreatic Neoplasms 3Neurofibrosarcoma 3Glioblastoma 3Gastrointestinal Stromal Tumors 3Chondrosarcoma, Extraskeletal Myxoid 3Advanced Cancers 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solitary Fibrous Tumors 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2

Interventions

enzalutamide 2pazopanib 1capivasertib 1Watchful Waiting 1STA 9090 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Dutasteride 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma of the Prostate × pazopanib × Clear all
NCT01832259 2018-12-12

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

University of Utah

Phase 2 Completed
30 enrolled 10 charts
Genitourinary

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡